Literature DB >> 10590259

Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5.

J Zhang1, R Kuvelkar, N J Murgolo, S S Taremi, C C Chou, P Wang, M M Billah, R W Egan.   

Abstract

mAb against human IL-5 inhibit pulmonary eosinophilia, tissue damage and airway hyper-reactivity in allergic animal models. Sch 55700 is a humanized, neutralizing anti-IL-5 antibody. To better understand the molecular mechanism by which Sch 55700 blocks IL-5 bioactivity, we have mapped its epitope by scanning IL-5 with synthetic peptides. Those peptides containing a region, ERRRV, corresponding to amino acids 89-93 of IL-5 specifically interact with both Sch 55700 and its parental rat IgG, 39D10. Among the five residues of this region, all three arginine residues were particularly critical for interaction of these peptides with Sch 55700. We further characterized this region by alanine scanning using site-directed mutagenesis. Examination of COS-expressed IL-5 mutants by Western blot showed that single mutations of E(89), R(90), R(91) or R(92) to alanine caused a loss of IL-5 binding to both Sch 55700 and 39D10. We further demonstrated in surface plasmon resonance studies using a BIAcore biosenosor that E(89), R(90) or R(91) are involved in the interaction between IL-5 and its receptor alpha subunit. Based upon the findings here and previously reported structures of the IL-5 and 39D10 variable region, we propose a model suggesting that the molecular interactions between the IL-5 and Sch 55700 mainly involve several ion pair interactions. We conclude that Sch 55700 occupies a region, ERRR, on IL-5 that is essential for its interaction with the receptor and thereby blocks IL-5 bioactivity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10590259     DOI: 10.1093/intimm/11.12.1935

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  19 in total

Review 1.  Progress in the use of biological assays during the development of biotechnology products.

Authors:  A R Mire-Sluis
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

Review 2.  Update on reslizumab for eosinophilic asthma.

Authors:  Juan Carlos Cardet; Elliot Israel
Journal:  Expert Opin Biol Ther       Date:  2015       Impact factor: 4.388

Review 3.  [Anti-interleukin-5 therapy for eosinophilic diseases].

Authors:  D Simon; L R Braathen; H-U Simon
Journal:  Hautarzt       Date:  2007-02       Impact factor: 0.751

Review 4.  Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.

Authors:  Zhaleh J Amini-Vaughan; Margarita Martinez-Moczygemba; David P Huston
Journal:  Curr Allergy Asthma Rep       Date:  2012-10       Impact factor: 4.806

Review 5.  Reslizumab in Eosinophilic Asthma: A Review.

Authors:  Emma D Deeks; Guy Brusselle
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

Review 6.  Biologic agents for severe asthma patients: clinical perspectives and implications.

Authors:  Massimo Caruso; Jaymin Morjaria; Rosalia Emma; Maria Domenica Amaradio; Riccardo Polosa
Journal:  Intern Emerg Med       Date:  2017-12-14       Impact factor: 3.397

7.  Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.

Authors:  Erminia Ridolo; Francesco Pucciarini; Maria Cristina Nizi; Eleni Makri; Paola Kihlgren; Lorenzo Panella; Cristoforo Incorvaia
Journal:  Hum Vaccin Immunother       Date:  2020-05-13       Impact factor: 3.452

8.  Induction of lysosomal and plasma membrane-bound sialidases in human T-cells via T-cell receptor.

Authors:  Peng Wang; Ji Zhang; Hong Bian; Ping Wu; Reshma Kuvelkar; Ted T Kung; Yvette Crawley; Robert W Egan; M Motasim Billah
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

9.  Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies.

Authors:  Elizabeth A Jacobsen; David J Jackson; Enrico Heffler; Sameer K Mathur; Albert J Bredenoord; Ian D Pavord; Praveen Akuthota; Florence Roufosse; Marc E Rothenberg
Journal:  Annu Rev Immunol       Date:  2021-03-01       Impact factor: 28.527

Review 10.  Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease.

Authors:  S Greenfeder; S P Umland; F M Cuss; R W Chapman; R W Egan
Journal:  Respir Res       Date:  2001-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.